Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Phase 2
Recruiting
- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT06868290
- Locations
- 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇸🇬Novartis Investigative Site, Singapore, Singapore
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Phase 2
Not yet recruiting
- Conditions
- Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT06865651
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT06857955
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Phase 3
Not yet recruiting
- Conditions
- Kidney DiseasesKidney Diseases, ChronicUrological DiseasesGlomerulonephritisGlomerular DiseaseGlomerulonephritis, IGAGlomerulopathyImmunoglobulin Disease
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT06858319
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Not yet recruiting
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2382
- Registration Number
- NCT06858332
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5448
- Registration Number
- NCT06854341
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Phase 3
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 486
- Registration Number
- NCT06855277
Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study
Not yet recruiting
- Conditions
- Kidney Diseases
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06851845
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Phase 3
Not yet recruiting
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Remibrutinib oral treatment
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT06846281
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Phase 2
Active, not recruiting
- Conditions
- IgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06841094
- Locations
- 🇪🇸
Hospital Ribera Polusa, Lugo, Spain
🇪🇸Hospital Universitario De Getafe (HUG), Madrid, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath